AI assistant
Sending…
NEKTAR THERAPEUTICS — Director's Dealing 2017
Dec 20, 2017
32134_dirs_2017-12-19_3b2efa07-c01b-4cd0-b659-ce4548a55bda.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2017-12-15
Reporting Person: Nicholson John (SVP & Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-12-15 | Common Stock | A | 26000 | $0.00 | Acquired | 272536 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-12-15 | Stock Option | $56.90 | A | 65000 | Acquired | 2025-12-14 | Common Stock (65000) | Direct |
Footnotes
F1: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service.
F2: This stock option vests over four years in equal monthly installments based on continued service.
More from NEKTAR THERAPEUTICS
Regulatory Filings
2026
May 8
Annual Report
2026
Apr 24
Regulatory Filings
2026
Apr 23
Regulatory Filings
2026
Apr 23
Regulatory Filings
2026
Apr 20
Regulatory Filings
2026
Apr 20
Regulatory Filings
2026
Apr 20
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Feb 20
Director's Dealing
2026
Feb 20